专利号:WO-2022256490-A9 优先权日:2021-06-03 标题:Improved synthesis of phosphoramidates for the treatment of hepatitis b virus 发明人:LOCKWOOD MARK 权利人:ANTIOS THERAPEUTICS INC 摘要:The synthesis of phosphoramidate prodrugs useful in the treatment of viral infections is disclosed. Specifically, an improved synthesis of phosphoramidate nucleotides useful in the treatment of Hepatitis B virus is disclosed.
专利号:US-8278483-B2 优先权日:2006-02-07 标题:Process for synthesis of glycomimicking cationic amphiphiles 发明人:MAHIDHAR YENUGONDA VENKATA; CHAUDHURI ARABINDA; MUKHERJEE RAMA 权利人:MAHIDHAR YENUGONDA VENKATA; CHAUDHURI ARABINDA; MUKHERJEE RAMA; COUNCIL SCIENT IND RES 摘要:The present invention provides processes for the synthesis of novel Shikimic acid head-group containing non-toxic cationic amphiphiles capable of facilitating transport of biological macromolecules into cells.
专利号:US-10995093-B2 优先权日:2016-04-07 标 题 :Synthesis of 2′-fluoro-6′-methylene-carbocyclic adenosine (FMCA) and 2′-fluoro-6′methylene-carbocyclic guanosine (FMCG) 发明人:CHU CHUNG K; MULAMOOTTTIL VARUGHESE ALEXANDER; MISHRA RAM C; SINGH UMA SHARAN 权利人:UNIV GEORGIA 摘要:The invention provides a new convergent approach for the synthesis of 2′-fluoro-6′-methylene-carbocyclic adenosine (FMCA) and 2′-fluoro-6′-methylene-carbocyclic guanosine (FMCG) from a readily available starting material in eight steps. An efficient and practical methodology for stereospecific preparation of a versatile carbocyclic key intermediate, (1S,3R, 4R)-3-tert-butoxy-4-(tert-butoxymethyl)-2-fluoro-5-methylenecyclopentanol (compound 8 of scheme 1A or a) in only six (6) steps is also provided. Prodrugs of these compounds are also prepared.
专利号:WO-2023118363-A1 优先权日:2021-12-22 标题:Method for the synthesis of a carbonyl-functionalised adduct 发明人:GODEHARD SIMON P; PELZER ALEXANDER 权利人:BRAIN Biotech AG 摘要:The invention relates to a method for the synthesis of a carbonyl-functionalised adduct.
专利号:US-9334273-B1 优先权日:2014-03-05 标题:Efficient and stereoselective synthesis of 2′-fluoro-6′-methylene-carbocyclic adenosine (FMCA) 发明人:CHU DAVID C K; SINGH UMA S 权利人:UNIV GEORGIA 摘要:The invention provides a new convergent approach for the synthesis of 2′-fluoro-6′-methylene-carbocyclic adenosine (FMCA) from a readily available starting material (Vince lactam) in fourteen steps. An efficient and practical methodology for stereospecific preparation of a versatile carbocyclic key intermediate, D -2′-fluoro-6′-methylene cyclopentanol by diazotization, elimination, stereoselective epoxidation, fluorination and oxidative reduction of the Vince lactam in twelve steps is also provided.
专利号:US-7582758-B2 优先权日:2004-06-08 标 题:Lewis acid mediated synthesis of cyclic esters 发明人:MARTIN KEVIN V 权利人:METABASIS THERAPEUTICS INC 摘要:Methods for the synthesis of cyclic phosphonic acid diesters from 1,3-diols are described, whereby cyclic phosphonic acid diesters are produced by reacting a chiral 1,3-diol and an activated phosphonic acid in the presence of a Lewis acid.
1: Lin RZ, Sun PJ, Tao Q, Yao J, Chen JM, Lu TB. Mechanism study on stability enhancement of adefovir dipivoxil by cocrystallization: Degradation kinetics and structure-stability correlation. Eur J Pharm Sci. 2015 Oct 10. pii: S0928-0987(15)30035-X. doi: 10.1016/j.ejps.2015.10.006. [Epub ahead of print] doi: 10.3760/cma.j.issn.1007-3418.2015.08.007. Chinese. Chinese. doi: 10.1155/2015/529636. Epub 2015 Aug 11. Review. 6: De Clercq E. Current treatment of hepatitis B virus infections. Rev Med Virol. 2015 Jul 23. doi: 10.1002/rmv.1849. [Epub ahead of print] doi: 10.1002/cmdc.201500183. Epub 2015 Jul 1. doi: 10.3760/cma.j.issn.1007-3418.2015.04.004. Chinese. doi: 10.1371/journal.pone.0131337. eCollection 2015. 10: Yang J, Chen G, Chen X, Zhang H, Jiang D, Yang G. Initial combination anti-viral therapy with lamivudine and adefovir dipivoxil decreases short-term fatality rate of hepatitis-B-virus-related acute-on-chronic liver failure. Virol J. 2015 Jun 24;12:97. doi: 10.1186/s12985-015-0323-3.
合成参考文献
参考文献:10.1111/j.1478-3231.2010.02207.x 摘要:Marcellin P, Sung J, Piratvisuth T. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. Liver Int. 2010 May;30(5):657–68. doi: 10.1111/j.1478-3231.2010.02207.x. 参考文献:10.1371/journal.pone.0021698 摘要:Feng J, Lu L, Hua C, Qin L, Zhao P, Wang J, Wang Y, Li W, Shi X, Jiang Y. High Frequency of CD4+CXCR5+ TFH Cells in Patients with Immune-Active Chronic Hepatitis B. PLoS ONE. 2011 Jul 07;6(7):e21698. doi: 10.1371/journal.pone.0021698. 参考文献:10.1155/2011/367908 摘要:Panjaworayan N, Brown CM. Effects of HBV Genetic Variability on RNAi Strategies. Hepatitis Research and Treatment. 2011 Jul 02;2011():1–8. doi: 10.1155/2011/367908. 参考文献:10.1111/j.1478-3231.2011.02593.x 摘要:Grabowski J, Yurdaydìn C, Zachou K, Buggisch P, Hofmann WP, Jaroszewicz J, Schlaphoff V, Manns MP, Cornberg M, Wedemeyer H; HIDIT-1 study group. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. Liver Int. 2011 Oct;31(9):1395–405. doi: 10.1111/j.1478-3231.2011.02593.x. 参考文献:10.1111/j.1440-1746.2011.06852.x 摘要:Kim YJ, Cho HC, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. J Gastroenterol Hepatol. 2012 Feb;27(2):306–12. doi: 10.1111/j.1440-1746.2011.06852.x.